多肽药物偶联物的结构组成及其抗肿瘤作用的研究进展  

Progress in the Structural Composition and Anti-tumor Effects of Peptide-Drug Conjugates

作　　者：张徽 刘晨 郝朝威 徐寒梅[1] ZHANG Hui;LIU Chen;HAO Chaowei;XU Hanmei(School of Life Science and Technology,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学生命科学与技术学院,江苏南京211198

出　　处：《药学进展》2024年第5期390-400,共11页Progress in Pharmaceutical Sciences

摘　　要：多肽药物偶联物(PDC)是一种新兴的靶向治疗药物,由连接子将肿瘤归巢肽与毒素共价偶联,以提高药物的肿瘤穿透性及靶向性、改善药物的水溶性及药物代谢动力学特征、降低药物的全身不良反应。通过对PDC药物中常用的归巢肽、连接子、毒素及PDC药物在肿瘤中的治疗作用进行阐述,期望更全面地了解PDC药物的研究进展,为肿瘤的靶向治疗提供新的可能性。Peptide-drug conjugate(PDC)is an emerging targeted therapy,which covalently couples tumor-homing peptide and toxin by linker to improve its tumor penetration and targeting,improve its water solubility and pharmacokinetic properties,and reduce its systemic adverse reaction.This article reviews the research progress in this field by introducing the tumor-homing peptides,linkers,toxins commonly used in PDC drugs and the role of PDC drugs in tumor treatment,hoping to understand the research progress of PDC drugs more comprehensively and provide new possibilities for targeted therapy of tumors.

关 键 词：多肽药物偶联物 肿瘤归巢肽 连接子 毒素 

分 类 号：R979.1[医药卫生—药品]